Vitestro
- Company typePrivate
- Founded2017
- HeadquartersUtrecht, Netherlands
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
Vitestro firmographics
Firmographics- Name
- Vitestro
- Legal name
- Vitestro B.V.
- Website
- https://vitestro.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
Vitestro industry classification
Industry- Product category
- Autonomous Robotic Phlebotomy Devices
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Quality Control, Calibrators, Standards & Proficiency Testing (IVD Consumables) (HLAHAAAL)
- akta.pro secondary industries
- Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics) (HLAHAAAN), In Vitro Diagnostics (IVD) Regulators (HLAJADAD)
Keywords
Where Vitestro is headquartered
LocationHeadquarters
- HQ city
- Utrecht
- HQ country
- Netherlands
- HQ region
- Europe
Offices1 record
Markets served
Vitestro business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Device sales (Aletta hardware): Sale of the Aletta® Autonomous Robotic Phlebotomy Device to hospitals and clinical laboratories. Vitestro aims to scale manufacturing and expand device sales globally, starting in Europe and the U.S.
- Implementation and customer success services: Joint project teams guide workflow preparation, site readiness, supervisor training through Vitestro Academy, on-site go-live support, and ongoing optimization — supporting initial device deployments and long-term operation.
- Technical and professional services: Ongoing technical services including proactive maintenance, remote support, system monitoring, queue management, workflow integration consulting, and corrective repairs to maximize device uptime.
Go-to-market motion3 records
Distribution channels3 records
Marketing channels8 records
Vitestro product offering
Product offeringCore offering
Vitestro develops and sells the Aletta® Autonomous Robotic Phlebotomy Device™ (ARPD™), a CE-marked medical device that autonomously performs diagnostic blood draws — from tourniquet application through vein selection, needle insertion, tube filling/inversion, and bandage placement — using multimodal imaging and AI-guided robotics. The device is complemented by Vitestro Academy supervisor training and Vitestro Professional & Technical Services covering implementation, workflow integration, maintenance, and ongoing customer success.
Product overview
Vitestro operates a single-product company model built around Aletta®, its flagship Autonomous Robotic Phlebotomy Device™ (ARPD™), rather than a multi-product platform. Aletta is the core offering and is complemented by two service-oriented modules that wrap around it: Vitestro Academy, the structured supervisor training program delivered as part of implementation, and Vitestro Professional & Technical Services, a customer-success bundle covering implementation guidance, workflow/queue optimization, and ongoing technical/maintenance support. The CE-marked Aletta device performs the full diagnostic blood draw autonomously using multimodal imaging and AI-guided robotics, and the Academy and Services modules are designed to enable successful deployment and day-to-day operation of that single core device at hospital and laboratory customer sites.
Differentiator
Problem solved
Functional benefit
Brands
- Aletta®: Aletta® is Vitestro's Autonomous Robotic Phlebotomy Device™ (ARPD™), a CE-marked medical device that automates the diagnostic blood collection process using multimodal imaging and AI.
Products and services
- Aletta® Autonomous Robotic Phlebotomy Device™ (ARPD™) Aletta® is the world's first Autonomous Robotic Phlebotomy Device™ (ARPD™). It performs the complete diagnostic blood draw procedure autonomously — applying the tourniquet, identifying a suitable vein via multimodal imaging (near-infrared + ultrasound + Doppler), performing venipuncture with submillimeter precision, filling and inverting tubes, and applying the bandage. CE-marked in the EU and used in clinical trials; not FDA-approved for the U.S. market.
- Vitestro Academy (Supervisor Training Program) Vitestro Academy provides structured training for hospital and laboratory supervisors who oversee Aletta devices. It is delivered as part of Vitestro's implementation and customer-success offering to build in-house expertise at customer sites.
- Vitestro Professional & Technical Services A bundled service offering supporting customers across the Aletta lifecycle — implementation guidance, workflow preparation, patient-flow and queue optimization, cubicle-layout advice, remote and on-site technical support, proactive maintenance, system monitoring, and corrective repairs.
Quantifiable outcome
- 94.5% first-stick success rate in the ADOPT multicenter trial (1,633 patients)
- +6 more outcomes
Companies that use Vitestro
Customer profileNamed customers13 records
Segments6 records
Ideal customer profiles3 records
Vitestro technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature7 records
Vitestro partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered core and flagship.
- BayCarecoreU.S. clinical research collaborator for Vitestro.
- Medical University of South Carolina (MUSC)coreU.S. clinical research collaborator for Vitestro.
- Baylor Scott & White Research InstitutecoreU.S. clinical research collaborator for Vitestro's U.S. market research initiatives.
- Advocate HealthcoreU.S. market research collaborator for Vitestro.
- Intermountain HealthcoreU.S. clinical research collaborator for Vitestro.
- Northwestern MedicineflagshipMulti-year collaboration with Vitestro (announced March 2025) to advance autonomous robotic phlebotomy in the U.S.; Northwestern is a U.S. clinical research collaborator supporting Vitestro's U.S. market entry.
- OLVG LabflagshipClinical study site for the A.D.O.P.T. trial and the first adopter of Aletta (Amsterdam, NL). Anja Leyte, CEO of OLVG Laboratories, is publicly cited as a customer reference.
- St. Antonius HospitalcoreClinical study site for the A.D.O.P.T. trial and an early adopter of Aletta (Utrecht, NL).
- Result LaboratoriumcoreClinical study site for the A.D.O.P.T. trial and an early adopter of Aletta (Dordrecht, NL).
- Amsterdam UMCcoreClinical study site for the A.D.O.P.T. trial and an early adopter of Aletta (Amsterdam, NL).
- Odense University Hospital (OUH) / Region of Southern DenmarkflagshipPre-ordered 3 Aletta devices in May 2024 — Vitestro's first international deployment outside the Netherlands. Marks the commercial launch of Aletta in Denmark.
Scale indicators10 records
Recent moves9 records
Expansion highlights6 records
Vitestro competitors and assessment
Company assessmentBroad incumbents
- Roche Diagnostics: Roche Diagnostics is one of the largest in-vitro diagnostics and clinical-chemistry companies globally and a major buyer-facing presence in hospital laboratories. It is a relevant comparable as a broad incumbent in the pre-analytical and laboratory-automation value chain that Vitestro's Aletta device is positioned to integrate with.
- Siemens Healthineers: Siemens Healthineers is a major diagnostics and medical-imaging company with a large installed base in clinical laboratories and blood-draw workflows. It is comparable to Vitestro as a broad incumbent whose customers (hospital labs) are the same buyers Vitestro is targeting for Aletta, and one of the players most likely to enter the autonomous phlebotomy category.
- Abbott: Abbott is a global diagnostics and medical-device leader with a significant presence in core laboratory, point-of-care, and pre-analytical workflows. It is comparable to Vitestro both as a potential competitor in automated phlebotomy and as a large incumbent whose hospital-lab customers overlap with Vitestro's target market.
- Stryker (MAKO Surgical): Stryker's MAKO platform is a leading orthopedic surgical robotics system and one of the few scaled medical-robotics franchises. It is comparable to Vitestro as a large medical-device incumbent with proven robotic-system commercialization capability in hospital settings.
- Intuitive Surgical: Intuitive Surgical pioneered robotic surgery with the da Vinci system and is the most successful medical robotics company globally. It is comparable to Vitestro both as a medical-robotics platform and via its co-founder Fred Moll, who sits on Vitestro's board and is widely regarded as the 'father of robotic surgery.'
- Becton Dickinson (BD): BD is one of the largest global medical-technology companies with a deep presence in diagnostics, specimen collection, and pre-analytical lab automation (including the BD Kiestra line, where Vitestro's VP of Engineering previously led R&D). BD is a relevant comparable as the dominant incumbent in the blood-collection workflow that Vitestro is seeking to automate.
Emerging players
- Tasso: Tasso manufactures patient-side, virtually painless blood-collection devices (OnDemand and M20) for at-home and decentralized sampling. It is comparable to Vitestro as a blood-collection innovation company targeting routine diagnostic draws, though it focuses on self-sampling at home rather than autonomous in-hospital robotics.
- Seventh Sense Biosystems: Seventh Sense Biosystems developed the TAP device, a push-button microneedle-based system for virtually painless capillary blood collection. It is comparable to Vitestro as an emerging blood-collection technology player focused on improving the patient experience of diagnostic sampling.
- Babson Diagnostics: Babson Diagnostics has built BetterWay, a fingertip-capillary blood-testing ecosystem that requires a fraction of the sample volume of venipuncture. It overlaps with Vitestro's mission of modernizing the routine diagnostic blood-draw workflow, though Babson focuses on capillary microsampling rather than autonomous venipuncture robotics.
Direct peers
- Velano Vascular: Velano Vascular develops needle-free blood-draw technology that enables vascular access from existing IV lines. It is the closest direct peer to Vitestro because both are commercial-stage medical-device companies innovating the diagnostic blood-collection workflow used by hospital phlebotomy departments.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks7 records
Key highlights7 records
Customer concentration
Vitestro social profiles
Digital presenceVitestro compliance and trust
Trust signalCompliance4 records
Vitestro financial estimates
Financial estimateRevenue estimate
Valuation estimate
Vitestro leadership team
Management profileNumber of profiles
Profiles15 records
Vitestro funding detail
Funding detailFunding overview
Funding rounds5 records
Investors16 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Vitestro M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Vitestro
What does Vitestro do?
Vitestro develops and sells the Aletta® Autonomous Robotic Phlebotomy Device™ (ARPD™), a CE-marked medical device that autonomously performs diagnostic blood draws — from tourniquet application through vein selection, needle insertion, tube filling/inversion, and bandage placement — using multimodal imaging and AI-guided robotics. The device is complemented by Vitestro Academy supervisor training and Vitestro Professional & Technical Services covering implementation, workflow integration, maintenance, and ongoing customer success.
Is Vitestro a public or private company?
Vitestro is a private company. It is classified as venture growth investor backed and is currently operating.
When was Vitestro founded?
Vitestro was founded in 2017. It employs 51 to 100 people.
Where is Vitestro based?
Vitestro is headquartered in Utrecht, Netherlands, in the Europe region.
How does Vitestro make money?
Three revenue lines are on record. Device sales (Aletta hardware) is the primary driver. The others are implementation and customer success services and technical and professional services.
Who are Vitestro's main competitors?
Broad incumbents on record are Roche Diagnostics, Siemens Healthineers, Abbott, Stryker (MAKO Surgical), Intuitive Surgical and Becton Dickinson (BD). Emerging players are Tasso, Seventh Sense Biosystems and Babson Diagnostics. Velano Vascular is listed as a direct peer.
Does Vitestro have an API?
No public API is recorded for Vitestro.
What industry is Vitestro in?
Vitestro's product category is Autonomous Robotic Phlebotomy Devices. Its primary akta.pro industry code is HLAHAAAL, Quality Control, Calibrators, Standards & Proficiency Testing (IVD Consumables), with a secondary code of HLAHAAAN, Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics). Its NAICS code is 325413 and its SIC code is 3841.